argenx SE (NASDAQ:ARGX) Shares Sold by Evolutionary Tree Capital Management LLC

Evolutionary Tree Capital Management LLC trimmed its position in shares of argenx SE (NASDAQ:ARGX) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,435 shares of the company’s stock after selling 37 shares during the period. argenx accounts for approximately 1.5% of Evolutionary Tree Capital Management LLC’s holdings, making the stock its 27th biggest position. Evolutionary Tree Capital Management LLC’s holdings in argenx were worth $1,477,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. J.Safra Asset Management Corp lifted its stake in shares of argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares during the period. Blue Trust Inc. raised its holdings in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. GAMMA Investing LLC lifted its position in argenx by 420.0% in the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after purchasing an additional 63 shares during the period. Mather Group LLC. bought a new position in argenx during the 1st quarter valued at $38,000. Finally, Lindbrook Capital LLC boosted its stake in argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after purchasing an additional 37 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ARGX shares. Evercore ISI upped their price objective on argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a report on Friday, July 12th. Guggenheim upped their price target on shares of argenx from $545.00 to $585.00 and gave the company a “buy” rating in a report on Friday, July 26th. Barclays raised shares of argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. William Blair reissued a “market perform” rating on shares of argenx in a research note on Monday, June 17th. Finally, Truist Financial lifted their price target on shares of argenx from $480.00 to $540.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and an average target price of $547.74.

argenx Stock Down 0.6 %

ARGX stock opened at $533.00 on Friday. The company has a 50 day moving average of $512.59 and a two-hundred day moving average of $432.76. The company has a market cap of $31.68 billion, a price-to-earnings ratio of -94.17 and a beta of 0.62. argenx SE has a 12-month low of $327.73 and a 12-month high of $554.74.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. During the same quarter last year, the firm earned ($1.69) earnings per share. On average, research analysts anticipate that argenx SE will post -0.37 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.